Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trial-Reference-Cited by-同舟云学术

Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trial

Published:2024-08 Issue:8 Volume:25 Page:1003-1014
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Moreau Philippe,Hulin Cyrille,Perrot Aurore,Arnulf Bertrand,Belhadj Karim,Benboubker Lotfi,Zweegman Sonja,Caillon Hélène,Caillot Denis,Avet-Loiseau Hervé,Delforge Michel,Dejoie Thomas,Facon Thierry,Sonntag Cécile,Fontan Jean,Mohty Mohamad,Jie Kon-Siong,Karlin Lionel,Kuhnowski Frédérique,Lambert Jérôme,Leleu Xavier,Macro Margaret,Orsini-Piocelle Frédérique,Roussel Murielle,Schiano de Colella Jean Marc,van de Donk Niels WCJ,Wuillème Soraya,Broijl Annemiek,Touzeau Cyrille,Tiab Mourad,Marolleau Jean-Pierre,Meuleman Nathalie,Vekemans Marie-Christiane,Westerman Matthijs,Klein Saskia K,Levin Mark-David,Offner Fritz,Escoffre-Barbe Martine,Eveillard Jean-Richard,Garidi Réda,Hua Winnie,Wang Jianping,Tuozzo Alba,de Boer Carla,Rowe Melissa,Vanquickelberghe Veronique,Carson Robin,Vermeulen Jessica,Corre Jill,Sonneveld Pieter

Publisher

Elsevier BV

Reference32 articles.

1. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors;de Weers;J Immunol,2011

2. Direct in vitro comparison of daratumumab with surrogate analogs of CD38 antibodies MOR03087, SAR650984 and Ab79;Lammerts van Bueren;Blood,2014

3. Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma;Overdijk;MAbs,2015

4. The therapeutic CD38 monoclonal antibody daratumumab induces programmed cell death via Fcgamma receptor-mediated cross-linking;Overdijk;J Immunol,2016

5. Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma;Krejcik;Blood,2016

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A roadmap towards improving outcomes in multiple myeloma;Blood Cancer Journal;2024-08-12

2. Daratumumab maintenance in patients with myeloma;The Lancet Oncology;2024-08